Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience

Author(s): J. Harvey Turner

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 9 , 2009

Become EABM
Become Reviewer


Determination of individual pharmacokinetics in patients undergoing radiopharmaceutical therapy is essential to define critical normal organ dosimetry. Review of a 20 year single institution experience demonstrates practical methodology for routinely characterising pharmacokinetics in each patient and calculating safe, effective therapeutic activities predicated upon prescribed radiation absorbed doses to the critical organs. In particular the results achieved in over 100 unselected consecutive clinic patients treated with 131I-rituximab radioimmunotherapy for relapsed/refractory non- Hodgkins lymphoma have matched the ORR of 75% and CR 50% achieved in formal phase II clinical trial. The low level of myelotoxicity was attributed to prospective dosimetry in each patient and prescribed dose of 0.75 Gy to whole body. Radiopeptide therapy of progressive neuroendocrine tumours with 177Lu-octreotate, illustrates application of practical dosimetry using retrospective quantitative imaging to define individual pharmacokinetics. Further challenges of multimodality combination therapy using radionuclide cocktails, chemotherapy and antivascular therapy, which will perturb pharmacokinetics, will require creative dosimetric methodology for continued safe, effective clinical practice of therapeutic nuclear oncology.

Keywords: Radiopharmaceutical pharmacodynamics, Radionuclide dosimetry, Therapeutic Nuclear Oncology, Lutetium- 177, Rhenium-188

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [966 - 982]
Pages: 17
DOI: 10.2174/138161209787582020
Price: $65

Article Metrics

PDF: 3